Progress and introduction
of main products
Dual-target inhibition：Target TL1A and IL-23 p19, Expanded immune modulation
Synergistic effect: Outstanding synergistic potency in both in vivo and in vitro studies
Extended half-life: Less frequent dosing (2-3 months) and reduced medication cost
High safety profile: No immune complex formation, reducing immunogenecity risk
Convenient Sc. delivery: More patient-friendly than IV administration
Good Druggability: Low tendency to aggregate; Stability of high concentration formulation
LQ080 simultaneously blocks TL1A/DR3 and IL-23/IL-23R pathways, leading to:
Reduced Th1/Th17-driven inflammation leading lower IFNγ and IL-17 secretion
Enhanced immune regulation by suppressed inflammatory responses
Superior disease control was demonstrated in preclinical IBD and ear thickening models
IBD – Crohn’s Disease, Ulcerative Colitis
Route: Sc. injection
Half-life: Extended (2–3× longer than conventional antibody)
Dosing: Less frequent administration due to prolonged half-life
